ProQR (PRQR) details encouraging AX-0810 Phase 1 data and 2026 plans

Rhea-AI Filing Summary

ProQR Therapeutics N.V. submitted a report as a foreign private issuer to make public a new press release titled “ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook.” The press release, attached as an exhibit, highlights early safety and pharmacokinetic results for the AX-0810 program, the selection of development candidates, and the company’s outlook for 2026. ProQR also states that this information is incorporated by reference into several of its existing Form F-3 registration statements.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of January 2026

Commission File Number: 001-36622

PROQR THERAPEUTICS N.V.

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

On January 8, 2026, ProQR Therapeutics N.V. (“ProQR”) issued a press release entitled “ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ProQR hereby incorporates by reference the information contained herein into ProQR’s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, File No. 333-263166 and File No. 333-285767).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PROQR THERAPEUTICS N.V.
Date: January 8, 2026	By:	/s/ Dennis Hom
		Dennis Hom
		Chief Financial Officer

INDEX TO EXHIBITS

Number		Description
99.1		Press Release of ProQR Therapeutics N.V. on January 8, 2026.

FAQ

What did ProQR Therapeutics (PRQR) disclose in this January 2026 report?

ProQR disclosed that it issued a press release titled “ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook,” and furnished that release as an exhibit.

What is the main topic of ProQR Therapeutics' new press release mentioned in the 6-K?

The press release focuses on encouraging AX-0810 Phase 1 safety and pharmacokinetic (PK) data, the selection of development candidates, and ProQR’s outlook for 2026.

How does this 6-K affect ProQR Therapeutics' existing registration statements?

ProQR states that the information contained in this report is incorporated by reference into its registration statements on Form F-3 with File Nos. 333-282419, 333-270943, 333-263166 and 333-285767.

Which program is highlighted in ProQR Therapeutics' January 8, 2026 press release?

The press release highlights ProQR’s AX-0810 program, specifically Phase 1 safety and PK data for this candidate.

Who signed the January 2026 report for ProQR Therapeutics (PRQR)?

The report was signed on behalf of ProQR Therapeutics N.V. by Dennis Hom, Chief Financial Officer, dated January 8, 2026.

What exhibit is attached to ProQR Therapeutics' January 2026 6-K?

The 6-K includes Exhibit 99.1, which is the press release of ProQR Therapeutics N.V. dated January 8, 2026.